Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.

[1]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[2]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  B. Sandmaier,et al.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. , 2013, Blood.

[4]  Bruce R. Blazar,et al.  Advances in graft-versus-host disease biology and therapy , 2012, Nature Reviews Immunology.

[5]  Manuel Solano-Genesta,et al.  Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease , 2012, Haematologica.

[6]  D. Landsittel,et al.  Long-Term Effects of Alemtuzumab on Regulatory and Memory T-Cell Subsets in Kidney Transplantation , 2012, Transplantation.

[7]  Joshua Miller,et al.  Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. , 2012, Human immunology.

[8]  M. Flowers,et al.  Treatment of chronic graft-versus-host disease in 2011 , 2011, Current opinion in hematology.

[9]  J. Perkins,et al.  The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality , 2011, Haematologica.

[10]  B. Storer,et al.  Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. , 2011, Blood.

[11]  G. Mufti,et al.  Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. , 2011, Blood.

[12]  D. Porter,et al.  Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2011, Blood.

[13]  J. Klein,et al.  Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. , 2011, Blood.

[14]  C. Craddock,et al.  Unrelated donor peripheral blood stem cell transplants incorporating pre‐transplant in‐vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft‐versus‐host disease , 2011, British journal of haematology.

[15]  J. Kanda,et al.  Alemtuzumab for the prevention and treatment of graft-versus-host disease , 2011, International journal of hematology.

[16]  M. Gramatzki,et al.  Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective , 2011, Bone Marrow Transplantation.

[17]  M. Mohty,et al.  Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  J. Ijzermans,et al.  Investigation of Lymphocyte Depletion and Repopulation Using Alemtuzumab (Campath‐1H) in Cynomolgus Monkeys , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  B. Djulbegovic,et al.  Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  M. Egger,et al.  Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  C. Solano,et al.  Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  G. Ruiz-Delgado,et al.  Re: Alemtuzumab-induced resolution of pulmonary noninfectious complications in a patient with chronic graft-versus-host disease. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  S. Giralt,et al.  Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. , 2008, Biology of Blood and Marrow Transplantation.

[24]  G. Ruiz-Argüelles,et al.  Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  Tomoko Watanabe,et al.  CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. , 2006, Clinical immunology.

[26]  J. Ritz,et al.  Rituximab for steroid-refractory chronic graft-versus-host disease. , 2006, Blood.

[27]  L. Gerber,et al.  Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  P. Lachenbruch,et al.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  R. Krance,et al.  Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab , 2005, Bone Marrow Transplantation.

[30]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  D. Pillay,et al.  Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. , 2003, Blood.

[32]  K. Busam,et al.  Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. , 2003, Blood.

[33]  T. Dexter,et al.  Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. , 1993, Blood.

[34]  A. Barrett.  The Treatment of Chronic Graft Versus Host Disease , 1985 .

[35]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .